|
|
Likelihood of response to abiraterone or enzalutamide after initial response and PD with the other?Likelihood of response to abiraterone or enzalutamide after initial response and PD with the other?In a patient with a response and then disease progression on enzalutamide, what is the likelihood that a patient with mCRPC will derive clinically meaningful benefit that will be evident to the patient and/or physician with abiraterone? In a patient with a response and then disease progression on abiraterone, what is the likelihood that a patient with mCRPC will derive clinically meaningful benefit that will be evident to the patient and/or physician with enzalutamide?
Antonarakis ES et al. Androgen receptor splice variant AR-V7, and resistance to enzalutamide and abiraterone in men with metastatic castration resistant prostate cancer. Proc ASCO 2014;Abstract 5001. Antonarakis ES et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 2014;371(11):1028-38. Abstract Beer TM et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014;371(5):424-33. Abstract Chang KH et al. Androgen metabolism in prostate cancer: From molecular mechanisms to clinical consequences. Br J Cancer 2014;111(7):1249-54. Abstract Chang KH et al. Prostate cancer-from steroid transformations to clinical translation. Nat Rev Urol 2012;9(12):721-4. Abstract Ferraldeschi R et al. Molecular pathways: Inhibiting steroid biosynthesis in prostate cancer. Clin Cancer Res 2013;19(13):3353-9. Abstract Karantanos T et al. Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level. Eur Urol 2014;67(3): 470-9. Abstract Sharifi N. Minireview: Androgen metabolism in castration-resistant prostate cancer. Mol Endocrinol 2013;27(5):708-14. Abstract Sharifi N. Steroid sidestep: Evading androgen ablation by abiraterone. Clin Cancer Res 2014;[Epub ahead of print]. Abstract |